← All indications
Sleep Disorders, Intrinsic
Dyssomnias (i.e., insomnias or hypersomnias) associated with dysfunction of internal sleep mechanisms or secondary to a sleep-related medical disorder (e.g., sleep apnea, post-traumatic sleep disorders, etc.). (From Thorpy, Sleep Disorders Medicine, 1994, p187)
Subtype terms (5)
More specific conditions that are subtypes of Sleep Disorders, Intrinsic in the MeSH hierarchy.
- Disorders of Excessive Somnolence
18 drugs (10 approved, 8 experimental)
- Nocturnal Myoclonus Syndrome
- Restless Legs Syndrome
47 drugs (36 approved, 11 experimental)
- Sleep Apnea Syndromes
89 drugs (76 approved, 13 experimental)
- Sleep Initiation and Maintenance Disorders
169 drugs (79 approved, 90 experimental)
Drugs by status
Phase 4 trials (31)
- melatonin
- methylprednisolone
- ketamine
- diphenhydramine
- mometasone
- methylphenidate
- dupilumab
- tenofovir
- levetiracetam
- lemborexant
- lidocaine
- sufentanil
- emtricitabine
- tramadol
- trazodone
- rasagiline
- zolpidem
- calcium alginate
- dexmedetomidine
- bupropion
- losartan
- varenicline
- midazolam
- sodium chloride
- rilpivirine
- eszopiclone
- hydroxyzine
- esomeprazole
- armodafinil
- solriamfetol
- +1 more
Phase 3 trials (21)
Phase 2 trials (14)
Phase 1 trials (17)
Other trials (27)
- maltodextrin
- bifidobacterium animalis
- clobazam
- euphorbia
- carbocisteine lysine
- esketamine
- platelet-rich plasma
- tryptophan
- lavender
- acetaminophen
- caffeine
- honey
- remimazolam
- typhoid vaccine
- zaleplon
- citrus extract
- pistachios
- amino acids
- omega-3 fatty acids
- cherry
- saffron
- kiwi fruit
- gamma-aminobutyric acid
- lemon
- linoleic acid
- lactobacillus delbrueckii
- Diamine Oxidase
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 1 Indications (1)